Not Signed In - Arena Pharmaceuticals Completes Enrollment With 3,182 Patients In Lorcaserin Phase 3 BLOOM Trial For Obesity
Tue, 06 Feb 2007 08:00 AM EST
... Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it completed patient enrollment in the first of three planned Phase 3 pivotal trials evaluating the efficacy and safety of its lead drug candidate, lorcaserin hydrochloride, for the treatment of obesity. [click link for full article] ...
Related Topics
- Clinical Trials
- Obesity
- Overweight and Obesity
- Obesity and Overweight
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Bloom Syndrome
- Seizures (in about half of patients)
- What Your Female Patients Want to Know About Bladder Control
- Vaccinations For HIV/AIDs Patients
- Smoking Cessation and Continued Risk in Cancer Patients
- Approximately one-half of patients with small tumors will get back useful hearing in the affected ear after surgery.
- The Use of Acupuncture in Addiction and Obesity
- Shapedown Pediatric Obesity
- Obesity and Weight Management
- Obesity hypoventilation syndrome (OHS)
- Harmful Algal Blooms
- Most people with small tumors will have no permanent paralysis of the face after surgery. However, about two-thirds of patients with large tumors will have some permanent facial weakness after surgery.
- Desipramine
- Trastuzumab
email this page
print this page
bookmark this page
feedback on this page
